首页> 外国专利> Detoxification by means of the controlled, in vivo secretion triggered rupture of liquid membrane capsules

Detoxification by means of the controlled, in vivo secretion triggered rupture of liquid membrane capsules

机译:通过体内分泌的受控排毒触发液膜胶囊破裂

摘要

The present invention relates to liquid membrane capsules which rupture when contacted with biliary or pancreatic secretions in the intestine thereby releasing their contents in the intestine so the contents become fully available for the treatment of disease at that location in the animal or patient. Particularly, the rupturable liquid membrane capsules containing urease are used for the treatment of chronic uremia. The liquid membrane capsules comprise an internal aqueous phase which contains an oil insoluble medicinal of choice, some complexing agent, dietary supplement or enzyme particularly suited for the intended treatment. This internal aqueous and oil insoluble phase is encapsulated in a nonaqueous external phase comprising a biologically inert oil component, and a material which will complex with the biliary and/or pancreatic secretions in the intestine thereby causing the rupture of the external phase resulting in the release of the internal phase in the intestine. Thus, the internal phase is isolated during passage through the mouth, esophagus, and stomach. On the absence of this isolation the material might be an irritant or be degraded in some of these areas. PPThe invention is further related to a method of in vivo detoxification comprising the use of liquid membrane capsules containing detoxification materials such as medicinals and/or enzymes as an aqueous internal phase encapsulated in a continuous external phase comprising an oil which external phase further contains an additive which complexes with the biliary and/or pancreatic secretions in the intestine causing the rupture of the external phase, the detoxification process proceeding by the rupture of the external phase resulting in the release of the internal phase in the intestine. The internal phase in this case is such that it will bring about a conversion of certain toxins in the intestine to forms that can readily be trapped by conventional toxin trapping LMC as described by prior art.
机译:本发明涉及液膜胶囊,当其与肠中的胆汁或胰腺分泌物接触时破裂,从而在肠中释放它们的内含物,因此该内含物完全可用于治疗动物或患者中该部位的疾病。特别地,含有脲酶的可破裂液膜胶囊用于治疗慢性尿毒症。液体膜胶囊包含内部水相,其包含选择的油不溶性药物,某些络合剂,膳食补充剂或特别适合于预期治疗的酶。这种内部的水和油不溶性相被包裹在非生物的外相中,该非水相包含生物惰性的油成分,以及与肠中胆汁和/或胰腺分泌物复合的物质,从​​而导致外相破裂导致释放在肠内相。因此,在通过口腔,食道和胃的过程中,内相被隔离了。在没有这种分离的情况下,该物质在某些区域中可能是刺激性的或被降解的。本发明进一步涉及一种体内排毒的方法,该方法包括使用含有排毒材料的液体膜胶囊,例如用作药物和/或酶的水相内相,包封在包含油的连续外相中,该外相还包含与肠道中胆汁和/或胰腺分泌物复合的添加剂,导致外相破裂,排毒外部相的破裂导致肠内相释放的过程。在这种情况下,内相使得它将肠中的某些毒素转化为易于被现有技术描述的常规毒素捕获LMC捕获的形式。

著录项

  • 公开/公告号US4183960A

    专利类型

  • 公开/公告日1980-01-15

    原文格式PDF

  • 申请/专利权人 EXXON RESEARCH AND ENGINEERING;

    申请/专利号US19780874247

  • 发明设计人 TINA C. VOGLER;WILLIAM J. ASHER;

    申请日1978-02-01

  • 分类号A61K47/00;A61K37/48;

  • 国家 US

  • 入库时间 2022-08-22 17:07:56

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号